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A B S T R A C T
Work published over the past 10–15 years has caused the neuroscience community to engage in a
process of constant re-evaluation of the roles of glial cells in the mammalian central nervous system.
Recent emerging evidence suggests that, in addition to carrying out various homeostatic functions
within the CNS, astrocytes can also engage in a two-way dialogue with neurons. Astrocytes possess many
of the receptors, and some of the ion channels, present in neurons endowing them with an ability to
sense and respond to an array of neuronal signals. In addition, an expanding number of small molecules
and proteins have been shown to be released by astrocytes in both health and disease. In this
commentary we will highlight advances in our understanding of G protein-coupled receptor signalling in
astrocytes, with a particular emphasis on metabotropic glutamate (mGlu) receptors. Discussion will
focus on the major mGlu receptors expressed in astrocytes, mGlu3 and mGlu5, how these receptors can
inﬂuence different aspects of astrocyte physiology, and how signalling by these G protein-coupled
receptors might change under pathophysiological circumstances.
 2012 Elsevier Inc. 
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Two major classes of cells in the CNS are neurons and glia. While
glial cells substantially outnumber neurons in the brains of
rodents, these cell-types are present in approximately equal
number in the human brain [1]. However, the ratio of glia to
neurons differs between brain structures; varying from around
17:1 in thalamus to 1:10 in cerebellum, with the ratio being
approx. 3:2 in cerebral cortex [1]. For many years, glial cells were
considered to fulﬁl a structural/connective role and to provide
homeostatic support for neurons, for example, by contributing to
the regulation of the ionic (and nutrient) composition of the
extracellular millieu. Today, while glial cells are unlikely ever to
achieve status parity with neurons, at least in the eyes of the
majority of neuroscientists, their importance in an ever increasing
array of CNS functions is becoming much clearer. Cells too often
dismissed in the past simply as ‘‘neuron-supporting’’ cells are at
last beginning to engage and fascinate researchers, and to reveal a
breadth of importance in many aspects of CNS function [2,3] that
would have been inconceivable only a few years ago.
Glial cells can be sub-divided into microglia and macroglia.
Microglia are generally considered to be the immune cells of the
CNS, and are responsible for protecting the brain against* Corresponding author. Tel.: +44 116 229 7146; fax: +44 116 252 5045.
E-mail address: jc36@leicester.ac.uk (R.A. John Challiss).
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Open access under CC BY license.infection and damage by participating in inﬂammatory
responses (see [4] for recent review). Of the different types of
macroglia, astrocytes are the predominant subtype in the CNS
and can be divided into two main categories, ﬁbrous and
protoplasmic, which have different morphologies and localiza-
tions in the CNS, and may carry out both common and distinct
functions [5]. Protoplasmic astrocytes are found primarily in the
grey matter, and are closely associated with synapses and blood
vessels. These cells have irregularly shaped cell bodies from
which thousands of ﬁne membranous processes emanate
allowing them to occupy a large territory (e.g. 70,000 mm3 in
the case of a protoplasmic astrocyte in rat hippocampal CA1
region; [6]). In contrast, ﬁbrous astrocytes are found primarily in
the white matter, have fewer and better-deﬁned processes and
are usually associated with neuronal axons.
2. Established and emerging roles of astrocytes in the CNS
2.1. Homeostatic functions
The location of individual astrocytes within the CNS is highly
organized, with each cell occupying a distinct functional domain.
Astrocytes are often coupled to neighbouring astrocytes via gap
junctions, but can uncouple from the syncytial network in
response to changes in the extracellular environment (e.g.
acidiﬁcation). Astrocytes also possess a number of transporters
and enzymes enabling them to regulate both intracellular and
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 and Na+/Cl/HCO3
 co-
transporters, the vacuolar-type H+-ATPase and members of the
monocarboxylic acid transporter family [7]. Astrocytes express
carbonic anhydrase, which facilitates conversion of CO2, released
from neurons, into HCO3
 and H+, and which can then efﬂux from
astrocytes via transporters for these ions [7].
Other functions of astrocyte gap junctions include communi-
cation throughout the syncytium via Ca2+ waves [8], transport of
nutrients from the bloodstream to neurons [9], and the buffering of
ions accumulating in the extracellular space following neuronal
activity [10]. For example, K+ ion concentration can increase in the
extracellular space during normal neuronal excitation, and this can
lead to depolarization of neurons if not appropriately buffered.
Astrocytes are proposed to possess a redistributive ability; taking
up K+ ions in areas where their concentration is rising and
extruding them in regions where the concentration of K+ ions is
lower [11]. Astrocytes can take up K+ ions via a number of uptake
mechanisms, including Na+,K+-ATPases, transporters and K+
channels, and express Na+/K+ and K+/Cl co-transporters and high
levels of inwardly rectifying K+ channels at their endfeet.
Another well established function of astrocytes is the removal
of neurotransmitters from the extracellular space, through the
expression of an array of neurotransmitter transporters. Astrocytes
are the principal cell-type expressing two high-afﬁnity, Na+-
dependent glutamate transporters, EAAT1 (GLAST; SLC1A3) and
EAAT2 (GLT-1; SLC1A2) [12]. While some synaptically released
glutamate can be taken up by pre- or postsynaptic transporters, or
can diffuse away from the synapse, the vast majority of glutamate
uptake is carried out by these astrocyte transporters [12,13].
Glutamate taken up by astrocytes is rapidly converted by
glutamine synthase to glutamine, which can be cycled back to
neurons, where it is re-converted to glutamate by glutaminase.
Astrocytes can adapt rapidly to changes in synaptic activity,
through changes in the morphology of the cell (peripheral
astrocyte processes) at the synapse [13] and metabolic adaptation
(e.g. altered expression of glutamine synthase). This suggests that
astrocytes have the capacity dynamically to adjust key compo-
nents of the glutamate-clearance/recycling machinery according
to demand. Astrocytes are also implicated in the clearance of GABA
and glycine from the synaptic cleft through the expression of GABA
(GAT-1 and GAT-3) and glycine transporters. However, the role of
astrocytes in compartmentation of inhibitory neurotransmitters is
likely to be contributory rather than pre-eminent [14].
2.2. Energy and metabolism
Astrocytes provide neurons with the substrates necessary for
maintenance of neurotransmission (see [15] for review). As
discussed above, astrocytes are responsible for transporting and
metabolizing glutamate (and other transmitters) into precursors
required for the re-synthesis of these neurotransmitters within
neurons. The uptake of glucose is thought to occur via glucose
transporters (primarily GLUT1). Astrocytes possess enzymes
required for glycogen synthesis and breakdown, and in the adult
CNS glycogen stores are found primarily in astrocytes. During
periods of increased energy demand, or during hypoglycaemia,
astrocytes glycolytically metabolize glycogen to lactate, which is
released into the extracellular space, to be taken up by neurons for
oxidative metabolism. Depletion of astrocytic glycogen stores, or
inhibition of monocarboxylate transporters, results in accelerated
compound action potential failure recorded from rat optic nerve
following periods of high neuronal activity, even in the presence of
normal levels of glucose. Using ﬂuorescent glucose analogues,
Rouach et al. [16] have shown that gap junctions can allow passage
of glucose across astrocytic networks. In addition, glutamate
released by spontaneous or evoked neuronal activity can stimulateAMPA receptor-dependent increases in the intercellular diffusion
of glucose through connexon-dependent networks of hippocampal
astrocytes [16]. The importance of metabolic cross-talk between
astrocytes and neurons has been highlighted further by studies in
EAAT1 knockout mice, showing that glucose utilization, lactate
release and glutamate uptake by astrocytes in response to
glutamate were reduced compared to wild-type mice. Recently,
glial glycogenolysis and lactate export has been proposed to play a
crucial role in long term memory formation [17] providing a
complementary mechanism of astrocyte–neuronal interdepen-
dency alongside a D-serine release mechanism hypothesized to be
crucial in establishing memory [18].
2.3. Formation and maintenance of functional synapses
Astrocytes play an important role in the formation of functional
synapses, a process known as synaptogenesis (see [19] for review).
During development, astrocytes have been shown to act as
boundaries to guide neurites to their targets. When retinal
ganglion cells are puriﬁed in the absence of glial cells, their
synaptic activity is severely impaired, however, when co-cultured
with astrocytes, but not with other cell-types, such as oligoden-
drocytes, their synaptic activity is signiﬁcantly enhanced [20]. A
study by Ullian et al. [21] demonstrated that astrocytes increase
the number of mature and functional synapses between retinal
ganglion cells: not only were astrocytes important for increasing
the number of synapses, but they also played a role in augmenting
their function in vitro. These and other studies highlight the
importance of astrocytes and astrocyte-derived signals, in the
development and function of synapses in the CNS.
Astrocytes are also implicated in the removal (‘pruning’) of
synaptic connections, a process vital for controlling and reﬁning
the connectivity of mature neuronal circuits [22]. Elimination of
unwanted synapses is mediated by the classical complement
cascade, and complement component 1q (C1q) is a protein that
initiates this pathway. In the mature CNS, little C1q protein is
expressed, but postnatal neurons express C1q in response to
immature astrocytes. Astrocytes release signals which effectively
‘tag’ synapses to be pruned with C1q, leading to the accumulation
of complement component C3, which in turn leads to the
recognition of synaptic terminals by microglia and subsequent
phagocytosis [20]. In addition, astrocytes may also inﬂuence
synaptic function by the release of growth factors. For example, on
chronic blockade by tetrodotoxin, or by application of tumour
necrosis factor-a (TNFa), the expression of AMPA receptor in
hippocampal neurons is increased. TNFa is released from glial cells
on chronic activity blockade to increase AMPA receptor expression
and thereby increase synaptic strength [23].
Therefore, not only are astrocytes involved in the formation of
synapses during development, the maintenance and pruning of
synapses to form mature neural circuits, but glial cells are also
implicated in the moment-to-moment regulation of synaptic
function in response to increasing or decreasing neuronal activity.
2.4. Bi-directional communication with neurons
Considerable evidence now supports the concept that astro-
cytes can communicate with neurons in a bidirectional manner,
giving rise to the term ‘tripartite synapse’, where a synapse
possesses not only pre- and postsynaptic neuronal elements, but
also an astrocytic component [24]. Release of neurotransmitters,
such as glutamate and ATP, from presynaptic terminals, has been
shown to lead to activation of GPCRs and ligand-gated ion channels
in astrocytes. For example, glutamate stimulation of cultured
hippocampal astrocytes has been shown to lead to Ca2+ oscilla-
tions, and these Ca2+ responses can propagate intercellularly [8]. In
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increases in neuronal cells [25,26].
Initial reports of glutamate release from astrocytes, following
intracellular Ca2+ elevation, prompted further investigations into
the release of a range of ‘gliotransmitters’ (e.g. glutamate, ATP, D-
serine). The Ca2+-dependent release of glutamate from astrocytes
and consequent alterations in neuronal excitability has been
reported by a number of groups. For example, stimulation of
Schaffer collaterals induces not only a fast, excitatory postsynaptic
current in CA1 hippocampal neurons, but also a delayed, slower
inward current, thought to be mediated by glutamate release from
astrocytes acting at extra-synaptic NMDA receptors [27]. Gluta-
mate release from astrocytes not only can cause increases in
neuronal excitability, but also can inﬂuence presynaptic neuro-
transmitter release: for example, release of glutamate from
astrocytes following P2Y1 purinoceptor activation, leads to an
activation of presynaptic NMDA receptors promoting neurotrans-
mitter release [28]. Glutamate release from astrocytes not only
promotes neurotransmitter release in nearby neurons, but can also
inhibit neurotransmitter release, leading to heterosynaptic de-
pression [29].
Elevations in intracellular Ca2+ in astrocytes can also lead to
release of D-serine, a co-agonist at the NMDA receptor and ATP.
Release of D-serine from astrocytes is dependent on intracellular
Ca2+ elevation and is attenuated by inhibiting components
associated with the exocytotic machinery [30]. Similarly, an
intimate link between astrocyte Ca2+ and ATP release has been long
established [31]. Some studies provide support for the idea that
astrocytic ATP is released via a vesicular mechanism: thus,
Pangrsic et al. [32] found that glutamate stimulation of astrocytes
leads to an increase in the fusion of ATP-containing vesicles with
the membrane, while a recent study has implicated gliotransmitter
release from both small vesicle and lysosomal organelles [33].
However, there is also evidence that ATP release may occur
independently of a vesicle-dependent mechanism, but may instead
involve the movement of ATP through pores formed by trans-
membrane protein complexes, including connexins and/or pan-
nexins.
The presently available literature indicates that physiological
and pathophysiological changes in neuronal activity can increase
astrocytic Ca2+, which can in turn promote ‘gliotransmission’ to
evoke responses in adjacent neurons. While this demonstrates the
existence of bidirectional communication between astrocytes and
neurons, much of the mechanistic detail remains speculative and
controversial, not least the processes regulating gliotransmitter
release from astrocytes [34].
2.5. Regulation of cerebral blood ﬂow
When neurons in the CNS are highly active, regional blood ﬂow
adjusts to match the increased energy demand; a process called
functional hyperaemia. A number of studies have implicated
astrocytes in this process (see [35] for review). Astrocytic processesTable 1
Classiﬁcation and localization of mGlu receptor subtypes in the CNS.
Receptor subtype Splice-variation Preferential signalling pa
Group I mGlu1 a, b, c, d PLC 
mGlu5 a, b PLC 
Group II mGlu2 – AC (inhibitory) 
mGlu3 – AC (inhibitory) 
Group III mGlu4 a, b AC (inhibitory) 
mGlu6 – (Gi/o-coupling) 
mGlu7 a, b AC (inhibitory) 
mGlu8 a, b, c AC (inhibitory) form endfeet contiguous with blood vessels, with astrocytic
endfeet ensheathing more than 99% of the cerebrovascular surface.
Astrocytes are therefore able to form a conduit between neurons
and blood vessels, enabling them to play a role in the tight coupling
between neuronal activity and cerebral blood ﬂow. As discussed
earlier, astrocytes are capable of releasing gliotransmitters, and
these include a number of vasoactive compounds, such as ATP,
adenosine, nitric oxide, prostaglandins, and epoxyeicosatrienoates
(EETs). Various groups have shown that [Ca2+]i increases within
astrocyte endfeet lead to increases in Ca2+-dependent phospholi-
pase A2 activity, and the release of arachidonic acid. This diffusible
metabolite can readily be transformed into an array of vasocon-
strictors (e.g. 20-hydroxyeicosatetraenoic acid) within smooth
muscle cells, or vasodilators (e.g. epoxyeicosatrienoic acids,
prostaglandin E2) within astrocytes [36]. Therefore, among many
other functions, neuron-to-astrocyte communication plays a
fundamental role in functional hyperaemia, and individual
astrocyte endfeet can mediate contrasting actions on arterial
smooth muscle tone.
3. Metabotropic glutamate (mGlu) receptors
As well as fulﬁlling a primary role in the clearance of glutamate
from synapses, astrocytes also possess receptors that allow this
excitatory neurotransmitter to inﬂuence astrocyte physiology and
pathophysiology. In addition, astrocytes not only accumulate
glutamate, but may also release it in a process referred to as
gliotransmission (see above), although this remains a controversial
and much debated area of research [34,37]. A range of glutamate
receptors, both ionotropic and metabotropic, have been reported
to be expressed by astrocytes. The ionotropic glutamate receptor
complement, which includes isoforms of AMPA/kainate and NMDA
receptors, has been reviewed recently by others (e.g. [38] for
review) and will not be discussed in detail here.
Glutamate-stimulated increases in phosphoinositide turnover
in astrocytes were ﬁrst observed 25 years ago [39], with evidence
for expression of Gi/o-linked metabotropic glutamate receptors
being reported later [40]. Subsequent work has indicated a
diversity of mGlu receptor subtypes (Table 1), some of which
are expressed by astrocytes (Table 2), with the mGlu5 and mGlu3
receptor subtypes generally being reported to predominate. Group
I (mGlu5) and II (mGlu3) mGlu receptor activation can indepen-
dently or cooperatively regulate a number of aspects of astrocyte
function, including glutamate transporter activity and gliotrans-
mission to effect astrocyte–arteriolar and astrocyte–neuronal
communication (see below).
3.1. mGlu5 receptor signalling in astrocytes
Group I mGlu receptors primarily couple to Gaq/11 proteins to
stimulate phospholipase Cb activity, hydrolyse inositol phospho-
lipids and generate diacylglycerol (DAG) and inositol 1,4,5-
trisphosphate (IP3), which respectively activate DAG-dependentthway Location Knock-out mouse
Postsynaptic (some presynaptic) Yes [116]
Postsynaptic (some presynaptic) astrocytes Yes [117]
Presynaptic Yes [118]
Presynaptic astrocytes Yes [119]
Presynaptic Yes [120]
Retinal ON-bipolar cells Yes [121]
Presynaptic Yes [122]
Presynaptic Yes [123]
Table 2
Regional heterogeneity of mGlu receptor-subtype expression in astrocytes.
mGlu receptor
subtype
Expression in glial cells
mGlu1 Weak mRNA detection in the thalamus [50]
Expression is detected in spinal cord astrocytes [124,125]
mGlu2 Not expressed in astrocytes
mGlu3 Strong detection of mRNA in cultured astrocytes from
cortex, thalamus, tegmentum, hippocampus and striatum.
Weak signal for mRNA expression in cerebellum [50,126]
mGlu4 Weak signal for mRNA expression in the tegmentum and
striatum [50]
mGlu5 Strong detection of mRNA in cultured astrocytes from
cortex, thalamus, tegmentum, hippocampus and striatum.
Weak signal for mRNA expression in cerebellum [50,51]
mGlu6 Weak signal for mRNA expression in the tegmentum
and striatum [50]
mGlu7 Weak mRNA detection in the cerebellum and
tegmentum [50]
mGlu8 Weak mRNA detection in the cerebellum and
tegmentum [50]
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Despite this common signal transduction mechanism, mGlu1 and
mGlu5 receptors can, nevertheless, elicit very different single-cell
Ca2+ responses, with stimulation of the mGlu1 receptor generally
causing peak-plateau-type changes in intracellular Ca2+ concen-
tration ([Ca2+]i), whereas stimulation of mGlu5 receptors often
leads to robust oscillatory changes in [Ca2+]i [44–46]. Importantly,
mGlu5 receptor-stimulated Ca2+ oscillations have been shown to
occur in parallel with, and as a consequence of, synchronous
changes in IP3 concentration [47]. A mechanism, termed ‘‘dynamicFig. 1. ‘Dynamic uncoupling’ at the mGlu5 receptor. Activation of PKC(s) leads to phospho
associated G protein. Protein phosphatase(s) are proposed to restore G protein coupling
and dephosphorylation give rise to Ca2+ oscillations.uncoupling’’ (Fig. 1), has been proposed that involves the rapid
switching on and off of receptor-G protein coupling through PKC-
dependent phosphorylation (uncoupling receptor from G protein)
and protein phosphatase-dependent dephosphorylation (re-cou-
pling receptor to G protein) [44,48]. Elegant work by [44]
comparing mGlu1 and mGlu5 receptor coupling to Ca2+ responses
demonstrated that a threonine residue at position 840 (Thr-840),
within the membrane proximal C-terminal tail of the mGlu5
receptor was a potential site for rapid, reversible, PKC-dependent
phosphorylation. However, more recently [46] have provided
evidence for PKC-dependent phosphorylation of an adjacent serine
residue (Ser-839) rather than Thr-840, with the latter residue now
being considered to have a permissive role in PKC-dependent Ser-
839 phosphorylation. Thus, mutation of Thr-840 to alanine in the
mGlu5 receptor does not affect Ca2+ oscillations evoked by
receptor stimulation; in contrast, when Ser-839 is mutated, Ca2+
oscillations are abolished, consistent with the conclusion that Ser-
839 is the crucial residue for phosphorylation and receptor-G
protein uncoupling [46].
In astrocytes, mGlu5 is the predominant or exclusive group I
mGlu receptor subtype expressed [49,50] and, in culture, astrocyte
mGlu5 receptor expression can be increased by growth factor
supplementation [51,52]. Activation of astrocyte mGlu receptors
causes Ca2+ oscillations [45,53–55] most likely via the dynamic
uncoupling mechanism (see Fig. 1) previously established in
mGlu5 receptor-expressing recombinant cell systems
[44,48,55,56]. The relationship between receptor activation and
Ca2+ oscillatory behaviour has also been explored in both
astrocytes and recombinant cell systems [48,55–57]. A striking
feature, ﬁrst observed in an inducible mGlu5 receptor expressionrylation of the mGlu5 receptor at Ser-839, leading to uncoupling of the receptor from
, by dephosphorylating the receptor at Ser-839. Repeated cycles of phosphorylation
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concentration is present to evoke a Ca2+ response, neither the
amplitude nor frequency of the Ca2+ oscillation changes signiﬁ-
cantly even if glutamate concentration is increased over a wide
range (Fig. 2; and see [48]). In contrast, altering the level of mGlu5
receptor expression has a profound effect on the Ca2+ oscillatory
frequency, with increasing mGlu5 receptor expression leading to
higher Ca2+ oscillatory frequencies in both recombinant and native
systems (Fig. 3; and see [48]). Although Ca2+ oscillation frequency
in astrocytes is affected to some extent by changes in glutamate
concentration, with high concentrations of glutamate often
causing a transition from a Ca2+ oscillatory to a peak-plateau
response, invariant Ca2+-oscillatory amplitude and frequency can
again be observed over a substantial glutamate concentration
range [55] suggesting that an individual astrocyte has a deﬁned
Ca2+ oscillatory frequency that is, at least in part, determined by
the level of mGlu5 receptor expression. Recently, a minimal
simulation model has been reported that can recapitulate the key
experimental observations and allows predictions to be made and
experimentally tested regarding this dynamic uncoupling mecha-
nism (see [58]).
3.2. Orthosteric and allosteric modulation of mGlu5 receptors
The activity of mGlu5 receptors can be manipulated pharma-
cologically by agents that act to mimic or block the actions of
glutamate (orthosteric agonists and antagonists), or by agents that
bind to other (allosteric) sites on the receptor to modulate
orthosteric ligand–receptor interactions (Table 3). While it has
proved difﬁcult to generate orthosteric ligands that are selective
between mGlu1 and mGlu5 receptors, some more recently0 20 0 40 0 60 0 80 0 100 0 120 0
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Fig. 2. Type 5 mGlu receptor-mediated single-cell calcium signalling. Effects of increas
mGlu5a cells (A) or astrocytes (B). Glutamate concentration (0.3–300 mM) was increme
modulator (PAM: CDPPB, 10 mM) causes a signiﬁcant increase in Ca2+ oscillation freque
astrocytes (D).discovered allosteric ligands show degrees of selectivity that
make them essentially receptor subtype-speciﬁc [59].
When observed at the single-cell level, mGlu5 receptor-
stimulated Ca2+ oscillation frequency in astrocytes can be
concentration-dependently increased (by positive allosteric mod-
ulators (PAMs); Fig. 2) or decreased (by negative allosteric
modulators (NAM)). This recapitulates pharmacologically the
effect of increasing or decreasing receptor expression and offers
the pharmacological potential to use PAMS and NAMs to not only
modulate, but also to ‘retune’ mGlu5 receptor-evoked Ca2+
oscillation frequency in astrocytes [55,60]. This latter property
may be of particular importance as pharmacologically resetting the
frequency of astrocyte Ca2+ oscillations may ‘‘re-programme’’ the
interpretation of initial glutamate-mGlu5 receptor binding event,
for example through the activation/repression of a subtly different
set of transcription factors [61–63].
3.3. Astrocytic targets of mGlu5 receptor activation
Astrocytes have the capacity to clear glutamate rapidly from the
synaptic cleft through expression of high-afﬁnity EAAT1/2 gluta-
mate transporters. In addition, expression of mGlu receptors in
astrocytes means that glutamate has the capacity to modulate
synaptic activity by altering transporter activity (in the shorter
term), or expression (in the longer term). Following acute
stimulation of mGlu5 receptors in growth-factor treated astrocytes
the activity of EAAT2 is enhanced showing that through this
receptor glutamate can modulate its own clearance during periods
of synaptic activity [64]. Thus, the mGlu5 receptor can act as a glial
sensor acutely altering glutamate clearance rates. In contrast,
chronic stimulation of mGlu5 receptors has been reported to result0 20 0 40 0 60 0 80 0
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Fig. 3. Effects of growth factor treatment on mGlu5 receptor-mediated single-cell Ca2+ responses in astrocytes. Astrocytes were grown for approximately 8 days in vitro prior
to the addition of G5 supplement for the indicated time-period. Changes in intracellular Ca2+ release following stimulation with a maximally effective concentration of
glutamate (300 mM) are shown. Expression of mGlu5 receptor increases with time following G5 supplement treatment, leading the observed increases in glutamate-
stimulated Ca2+ oscillation frequency.
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[65].
Increasing evidence suggests that astrocyte mGlu5 receptors
may also modulate synaptic activity by participating in bidirec-
tional communication with neurons. Pasti et al. [53] showed that
Ca2+ oscillations in astrocytes, triggered by neuronal stimulation,
or by exogenous application of an mGlu receptor agonist, result in
repetitive Ca2+ responses in neighbouring neurons, potentially due
to Ca2+-dependent release of glutamate (or other gliotransmitters)Table 3
Examples of orthosteric and allosteric ligands acting at mGlu5 and mGlu3 receptors.
Orthosteric agonist Competitive antagonist 
mGlu5 (S)-DHPG (group I) [127]
CHPG [128]
ACDPP [129] 
mGlu3 DCG-IV (group II) [140]
NAAG [141]
LY379268 (group II) [142]
LY404039 (group II) [143]
LY341495 (group II) [144]
MGS0039 [145]
(S)-DHPG, (S)-3,5-dihydroxyphenylglycine; CHPG, (RS)-2-chloro-5-hydroxyphenylglycin
hydrochloride; DFB, [(3-ﬂuorophenyl)methylene]hydrazone-3-ﬂuorobenzaldehyde; CP
dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]phenyl}-2-hydroxybenzamide; CDPPB, 3-c
nyl)-{3-[3-(4-ﬂuoro-phenyl)-[1,2,4]-oxadiazol-5-yl]-piperidin-1-yl}-methanone]; VU00
methyl-6-(phenylethynyl)pyridine hydrochloride; Fenobam; 1-(3-chlorophenyl)-3-(3-m
5-methylpyridine; CTEP, 2-chloro-4-((2,5-dimethyl-1-(4-(triﬂuoromethoxy)phenyl)-1H
hydroxy-4-[(3-methylphenyl)ethynyl]octahydro-1H-indole-1-carboxylate; DCG-IV, (1
NAAG, N-acetyl-L-aspartylglutamate; LY379268, (1S,2R,5R,6R)-2-amino-4-oxabicyclo[3
nylbicyclo[3.1.0]hexane-4,6-dicarboxylic acid; LY341495, 2-[(1S,2S)-2-carboxycyclopr
dichlorobenzyloxy)-6-ﬂuorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid; LY487379, N-(
lamine; MNI-137, N-(4-(2-methoxyphenoxy)phenyl)-N-(2,2,2-triﬂuoroethylsulphonyl
phenyl)-pyrazolo[1,5-a]pyrimidin-3-ylethynyl]-pyridine-3-sulphonic acid; RO5488608
yl)-biphenyl-3-sulphonic acid.from astrocytes. The frequency of mGlu receptor-mediated Ca2+
oscillations in astrocytes appears to be dictated by the level of
synaptic activity, suggesting that information may be transmitted
between neurons and astrocytes in the frequency of oscillations
[53]. In addition, activation of astrocyte mGlu5 receptors within
the nucleus accumbens lead to Ca2+ oscillations and the appear-
ance of slow, inward NMDA receptor-dependent currents in
medium spiny neurons, potentially mediated by glutamate
released from astrocytes [66]. Stimulation of astrocyte mGlu5PAM NAM
DFB [130]
CPPHA (group I) [131]
CDPPB [132]
ADX47273 [133]
VU0092273 [134]
MPEP [135]
Fenobam [136]
M-5MPEP [137]
CTEP [138]
AFQ056 [139]
LY487379 (group II) [146] MNI-137 [147]
RO4988546; RO5488608 [148]
e; ACDPP, 3-amino-6-chloro-5-dimethylamino-N-2-pyridinylpyrazinecarboxamide
PHA, N-[4-chloro-2-(phthalimidomethyl)phenyl]salicylamide N-[4-chloro-2-[(1,3-
yano-N-(1,3-diphenyl-1H-pyrazol-5-yl)benzamide; ADX47273, [S-(4-ﬂuoro-phe-
92273, (4-hydroxypiperidin-1-yl)(4-phenylethynyl)phenyl)methanone; MPEP, 2-
ethyl-5-oxo-4H-imidazol-2-yl)urea; M-5MPEP, 2-(2-(3-methoxyphenyl)ethynyl)-
-imidazol-4-yl)ethynyl)pyridine; AFQ056 (Mavoglurant), methyl (3aR,4S,7aR)-4-
R,2R)-3-[(1S)-1-amino-2-hydroxy-2-oxoethyl]cyclopropane-1,2-dicarboxylic acid;
.1.0]hexane-2,6-dicarboxylic acid; LY404039, ()-(1R,4S,5S,6S)-4-amino-2-sulpho-
opyl]-3-(9H-xanthen-9-yl)-D-alanine, MGS0039, (1R,2R,3R,5R,6R)-2-amino-3-(3,4-
4-(2-methoxyphenoxy)phenyl)-N-(2,2,2-triﬂuoroethylsulphonyl)pyrid-3-ylmethy-
)pyrid-3-ylmethylamine; RO4988546, 5-[7-triﬂuoromethyl-5-(4-triﬂuoromethyl-
, 30-(8-methyl-4-oxo-7-triﬂuoromethyl-4,5-dihydro-3H-benzo[b][1,4]diazepin-2-
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example, mGlu receptor-mediated Ca2+ increases in astrocytes
during periods of high neuronal activity have been shown to
release ATP, which acts on synaptic purinoceptors to increase the
strength (‘‘scaling’’) of all synapses of the neuron [67].
Astrocytic mGlu5 receptors may also be involved in the
regulation of cerebral blood ﬂow. Zonta et al. [68] have shown
that stimulation of neuronal afferents in freshly prepared cortical
slices causes dilation of cerebral arterioles, and this process is
dependent on mGlu receptor-mediated Ca2+ oscillations within
perivascular endfeet. Inhibition of glutamate-stimulated increases
in astrocyte [Ca2+]i by application of an mGlu receptor antagonist
impairs arterial vasodilation [68]. Increases in astrocyte [Ca2+]i
mediated by mGlu receptor activity can also lead to the opening of
Ca2+-activated maxi-K+ channels in astrocyte endfeet, leading to
the release of K+ onto arterial smooth muscle cells, contributing to
vasodilation [69].
3.4. mGlu3 receptor signalling in astrocytes
The group II metabotropic glutamate receptor, mGlu3, is widely
expressed in the CNS, in both neurons and glia [70]. In common
with astrocyte mGlu5 receptor expression, mGlu3 receptor
expression in rodent and human astrocytes in vitro can be up-
regulated by growth factors [65] and by proinﬂammatory
cytokines, which, in contrast, down-regulate mGlu5 receptor
expression [71]. Thus, the relative expression of the different mGlu
receptor subtypes in glial cells appears to be plastic and dependent
on the trophic support (and other factors, such as inﬂammation)
within the microenvironment.
Compared to studies of the mGlu5 receptor, the signalling
pathways modulated by astrocytic mGlu3 receptors has so far
received less attention. Early studies in astrocytes indicated that
mGlu receptors can couple negatively to adenylate cyclase via
pertussis toxin-sensitive G proteins [40,70]. Subsequent studies
showed that addition of agonists selective for group II mGlu
receptors (such as 2R,4R-APDC and LY379268) inhibit forskolin-
stimulated cyclic AMP accumulation in cultured astrocytes under
Ca2+-free conditions, but the same agonists increase this response
in the presence of physiological Ca2+ concentrations [72]. A
signalling mechanism consistent with these ﬁndings was proposed
involving phospholipase C-dependent adenosine release and
autocrine activation of Gs-coupled A2A adenosine receptors [72].
Previously, a similar positive modulation of b-adrenoceptor-
stimulated adenylate cyclase activity by co-activation of group II
mGlu receptors had been shown in astrocytes [73]. Therefore, the
effect of mGlu3 receptor activation on adenylate cyclase activity in
astrocytes may depend on other coincident receptor-mediated
inputs. In addition, the potential to stimulate the release of
adenosine may not have only an autocrine action [74], but may also
act on neuronal adenosine receptors to ﬁne-tune synaptic
transmission (see for example, [75]). Astrocyte mGlu3 receptors
can also link to a variety of other signal transduction mechanisms,
including phosphoinositide 3-kinase and ERK1/2 [74], and Akt/PKB
and NF-kB [76]. mGlu3 receptor activation can also alter cyclic
GMP turnover, perhaps via distinct signalling pathways in
astrocytes compared to neurons [77].
Subtype-selective mGlu receptor activation can occur in vivo
through the action of N-acetyl-L-aspartylglutamate (NAAG), a
dipeptide abundant in the CNS [78]. Although NAAG has been
reported to have a number of different actions, perhaps its clearest
activity is as an mGlu3 receptor-selective agonist. While some
uncertainties remain regarding the synthesis, degradation and
neuronal/glia distribution of NAAG, and its role in intercellular
communication [79], NAAG is likely to cause selective activation of
mGlu3 receptor signalling in astrocytes. On tantalizing possibilityis that NAAG is synthesized de novo in astrocytes from a precursor
(N-acetyl-L-aspartate) released by neurons, with the NAAG
produced being released to affect both the astrocyte itself, and
perhaps neuronally located mGlu3 receptors in the immediate
vicinity.
3.5. Astrocytic targets of mGlu3 receptor activation
Glial mGlu3 receptors have been implicated in a number of
studies to have a neuroprotective functions in the CNS. A potential
astrocyte mechanism to bring about this effect could be through
regulation of glutamate transporter activity and/or expression.
Exposure of astrocytes to group II mGlu receptor-speciﬁc agonists
has been shown to increase glutamate transporter expression [65]
and presumably to increase the capacity to clear glutamate from
the extracellular space. Group II mGlu receptor activation in
astrocytes can also prevent the down-regulation of astroglial
glutamate transporters induced by neurotoxic agents, such as 1-
methyl-4-phenylpyridium [80]. Recent studies have provided
direct evidence for the neuroprotective potential of group II mGlu
receptor stimulation in astrocytes against apoptosis of cultured
neurons and astrocytes, by up-regulating glutamate uptake
mechanisms in astrocytes [81].
Group II mGlu receptors can couple to phosphoinositide 3-
kinase and positively or negatively to individual mitogen-activated
protein kinase signalling pathways in astrocytes [74], leading to
the release of trophic factors such as transforming growth factor-b
(TGF-b), which in turn can protect striatal neurons against NMDA
receptor-mediated neurotoxicity [65]. Others have also shown that
increases in synthesis and release of TGF-b from astrocytes can
protect surrounding neurons from excitotoxic cell death [82].
Stimulation of mGlu3 receptors in cultured astrocytes induces an
increased synthesis and release of nerve growth factor and S-100b
protein, important factors in neuronal survival [83]. The use of
mGlu2 and mGlu3 receptor knockout mice has provided strong
evidence that the protective actions of mGlu2/3 agonists against
excitotoxic cell death are mediated solely by astrocytic mGlu3
receptors [84], and that this is the result of synthesis/release of
neuroprotective agents, and/or through regulation of glutamate
transporters in astrocytes.
4. Astrocyte mGlu receptor signalling in disease
In parallel with the emergence of new evidence for roles of
astrocytes in neuropsychiatric disease has been evidence impli-
cating mGlu receptors in many of the pathophysiological changes
observed.
Astrocyte dysfunction likely contributes to the pathogenesis of
epilepsy and reactive astrogliosis is often detected in the epileptic
brain [85]. As already discussed (see Section 2.1) an important
function of astrocytes is to buffer extracellular K+, to prevent
hyperactivity. A number of publications have highlighted a
dysfunction in K+ homeostasis within the epileptic brain. For
example, Hinterkeuser et al. [86] showed that inwardly rectifying
K+ currents in astrocytes were down-regulated in the CA1 region of
patients with epilepsy, suggesting that impairment in K+ clearance
by astrocytes might contribute to epileptic seizures. In addition,
altered astrocyte Ca2+ signalling in epilepsy may contribute to
paroxysomal depolarization shifts (abnormal and prolonged
depolarizations with repetitive spiking, characteristic of seizures)
and neuronal excitotoxicity after status epilepticus [87,88]. The
former study also showed that anti-epileptic drugs inhibit Ca2+
increases in astrocytes, and therefore, astrocytes may be consid-
ered key targets in the treatment of epilepsy. Alterations in the
expression and/or functions of glutamate transporters and mGlu
receptors in astrocytes have also been implicated in the
S.J. Bradley, R.A.J. Challiss / Biochemical Pharmacology 84 (2012) 249–259256pathogenesis of epilepsy. The expression of members of the mGlu
receptor family (mGlu3, mGlu5, and possibly mGlu8) has been
reported to be increased in hippocampal astrocytes in mouse
models of epilepsy [89], and in vivo administration of a negative
allosteric modulator (NAM) of the mGlu5 receptor has been shown
to provide signiﬁcant neuronal protection following the induction
of status epilepticus in a mouse model [88].
Astrocytes can contribute to the death of motor neurons in
familial [90,91] and sporadic [92] amyotrophic lateral sclerosis
(ALS). Furthermore, expression of a disease-causing human
superoxide dismutase mutation (SOD1G93A) in astrocytes alone
is sufﬁcient to cause motor neuron degeneration and recapitulate
many characteristics of ALS pathology [93]. In a SOD1G93A
transgenic ALS rat model mGlu5 receptor expression in astrocytes
has been shown to be up-regulated in late stage disease, but there
was also a loss of the protein kinase C-dependent increase in
EAAT2 transporter activity normally seen on mGlu5 receptor
activation [94]. Such a loss of feed-forward regulation of astrocytic
glutamate clearance might contribute to excitotoxic motor neuron
death.
Evidence of a role for astrocytes in a number of neurodegener-
ative diseases has also accumulated, and it is known that reactive
astrogliosis is a well-known feature of neurodegeneration in
amyotrophic lateral sclerosis, Parkinson’s disease and Alzheimer’s
disease (AD) [95,96]. Neuroanatomically AD is characterized by the
hallmark deposition of extracellular amyloid-b (Ab), which
accumulates in focal plaques at a relatively early stage of the
disease. Ab-containing plaques often co-localize (and perhaps
attract) microglia and astrocytes, suggesting that glia may play
some role in the progression of AD [97]. Astrocytes have been
shown to contain both full-length and N-terminally truncated
forms of Ab peptide, suggesting a clearance role for astrocytes. In
addition, a study by Wyss-Coray et al. [98] demonstrated that
cultured astrocytes have the capacity to remove and degrade Ab
deposits, but that this capability may be lost in disease, suggesting
that a dysfunction of astrocytes may precede and/or coincide with
the build-up of Ab accumulation in the AD brain. Furthermore,
disturbances of physiological Ca2+ signalling in astrocytes have
been reported in a transgenic model of AD, with global increases in
resting Ca2+ levels and Ca2+ waves being observed that originate
near to plaques and propagate over considerable distances [99].
Activation of astrocyte mGlu receptors can promote the non-
amyloidogenic processing of amyloid precursor protein [100]
suggesting a potential to reduce b-amyloid formation. In addition,
exposure of mouse astrocytes to b-amyloid has been reported to
up-regulate the mGlu5 receptor (at both a mRNA and protein level)
and to give rise to greater changes in [Ca2+]i on mGlu receptor
agonist addition [101]. Interestingly, in post-mortem human
hippocampal tissue co-staining for mGlu5 receptor and b-amyloid
has revealed increased receptor immunoreactivity co-localized
with plaques [101]. A direct interaction between b-amyloid
oligomers and the mGlu5 receptor at the cell-surface has also
been demonstrated in vitro in cultured rat hippocampal neurons
[102]. In the presence of b-amyloid oligomers, mGlu5 receptors
cluster, show reduced lateral mobility and trigger increases in
[Ca2+]i. This change in mGlu5 receptor stability and/or signalling
eventually leads to synapse deterioration and potentially
synaptic failure. Whether b-amyloid causes similar effects on
mGlu5 receptors in astrocytes has yet to be investigated. Finally,
Caraci et al. [103] have demonstrated complex, contrasting
effects of mGlu 2 and mGlu3 receptor activation on the toxicity
of b-amyloid oligomers in rat cortical neurons cultured in the
absence or presence of astrocytes. This work has clearly
demonstrated that astrocyte mGlu3 receptor activation is
neuroprotective, at least in part through the increased release
of transforming growth factor-b1.Thus, pharmacologically targeting the mGlu5 and/or mGlu3
receptor in astrocytes, using either subtype-selective orthosteric or
allosteric ligands may provide novel therapeutic strategies for the
prevention of neuronal injury in Alzheimer’s disease and in other
pathological conditions.
5. Conclusions
Are we entering a golden age in glial cell research? Certainly the
volume of research being published on all types of glia is growing
year-on-year. Despite this, it is difﬁcult not to conclude that our
understanding of glial cell physiology and pathophysiology
remains embryonic [20]. For example, while it is generally
believed that astrocytes fulﬁl important synthetic and secretory
roles there clearly remains disagreement on which transmitters/
trophic factors they can release and, if they do, by what
mechanism(s). In this context the publication of transcriptome
data for astrocytes [104] has been illuminating, and has provided
evidence implicating secretory lysosomes as a potential route by
which ATP and D-serine might be released [105,106]. The case for
glutamate release by astrocytes remains a matter of heated debate;
however, this should not detract from the proven ability of these
cells to respond to this transmitter and to clear it from the
extracellular environment in a regulated manner [34].
In this context, mGlu3 and mGlu5 receptors appear to provide
important mechanisms for astrocytes to sense and respond to
changes in glutamate. In the case of the mGlu5 receptor it is
presently unclear what, if any, signiﬁcance there is to this
receptor’s unusual regulation by rapid, reversible phosphorylation
and consequent propensity to generate a ‘‘hard-wired’’ Ca2+
oscillatory signal through dynamic uncoupling (see Section 3.1).
Nevertheless, it is tempting to speculate that the ability to generate
a cell-speciﬁc Ca2+ oscillatory frequency across an ascending and
descending range of glutamate concentrations might be important
in acute and/or longer term signalling. For example, a particular
tuning of Ca2+ oscillatory frequency (deﬁned by mGlu5 receptor
expression level or by other factors) may allow the astrocyte to
activate/repress particular subsets of genes through (Ca2+-depen-
dent) transcriptional regulation. Certainly, good evidence has
accrued that altering either the Ca2+ signature (oscillatory versus
peak-plateau) and/or oscillatory frequency can encode speciﬁc
cellular outcomes [61–63]. However, little information on whether
this occurs, or which facets of (patho)physiology might be
regulated, has so far been obtained in astrocytes. It is worth
noting that astrocytes express Ca2+-dependent transcription
factors, including NFAT [107,108] and it will be interesting to
establish if this transcription factor is similarly regulated by
dynamic uncoupling (via mGlu5 receptor-stimulated Ca2+ oscilla-
tions) as it is by other GPCRs mediating their actions through
mechanistically distinct, but more common, regenerative Ca2+
oscillatory mechanisms (see [109]). An additional complication for
astrocytes is the potential for Ca2+ changes (and perhaps Ca2+
oscillations) to spread through a syncytium of cells via gap
junctions. Although mGlu5 receptor-initiated Ca2+ oscillations
spreading from one cell to another has, to our knowledge, not been
reported, the fact that oscillations in IP3 concentration entrain Ca
2+
oscillations makes this possibility more likely, as the former
second messenger may be more free to cross between coupled cells
to propagate the signal across a linked network, in contrast to the
buffered, and consequently more spatially restricted Ca2+ ion.
Indeed, an intriguing possibility arises that by going from local to
global oscillatory signals a universal astrocyte transcriptional
programme might be coordinated across wide territories of the
CNS.
With respect to astrocyte mGlu5 receptor signalling, and Ca2+
homeostasis in this cell-type more generally, there remains so
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nothing about the importance of Homer proteins [110] in mGlu5
receptor location and signalling, beyond the fact that astrocytes
express some isoforms of Homer [111,112], and how this might
inﬂuence mGlu5 receptor-Ca2+ signalling in health or disease.
Exciting new discoveries are constantly being made that often
cause us to reassess and reformulate our understanding of
astrocyte Ca2+ homeostasis. Very recent discoveries in this respect
include (i) the previously unexplored role of TRPA1 receptors as
contributors to local basal [Ca2+]i in astrocytes and the inﬂuence
that modulating this plasma membrane ion channel can have on
the kinetics of GABA clearance from the extracellular environment
through altered astrocyte trafﬁcking of GAT-3 [113]; (ii) the
potential of astrocytes to sense the changes in extracellular [Ca2+]
that occur at synapses and to release ATP (likely via connexin
hemichannels) to modulate neural circuitry [114]; and (iii) the
additional inﬂuence of microglia on astrocyte–neuron intercom-
munication to add an additional complexity to non-neuronal
modulation of transmission [115]. It is hoped that through a
growing appreciation of astrocyte Ca2+ homeostasis we can begin
to understand how druggable targets, such as the mGlu5 and
mGlu3 receptors, can be exploited therapeutically in an array of
CNS disorders.
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